Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H28N4O11 |
| Molecular Weight | 608.5528 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC(CO)NN1C(=O)C2=C(C1=O)C3=C(N([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C5=C3C=CC(O)=C5)C6=C2C7=C(N6)C=C(O)C=C7
InChI
InChIKey=QMVPQBFHUJZJCS-NTKFZFFISA-N
InChI=1S/C29H28N4O11/c34-7-10(8-35)31-33-27(42)20-18-13-3-1-11(37)5-15(13)30-22(18)23-19(21(20)28(33)43)14-4-2-12(38)6-16(14)32(23)29-26(41)25(40)24(39)17(9-36)44-29/h1-6,10,17,24-26,29-31,34-41H,7-9H2/t17-,24-,25+,26-,29-/m1/s1
| Molecular Formula | C29H28N4O11 |
| Molecular Weight | 608.5528 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Edotecarin (J-107088 or [6-N-(1-hydroxymethyl-2-hydroxy)ethylamino-12,13-dihydro-2,10-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carb azo le-5,7(6H)-dione]) is a DNA topoisomerase I inhibitor. The antitumor activity of edotecarin has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in breast, cervix, pharynx, lung, prostate, colon, gastric, and hepatic cancer models. Banyu Pharmaceutical Co Ltd and Pfizer Inc were developing edotecarin for the potential treatment of solid tumors. Edotecarin development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16819636
The recommended Phase II dose of edotecarin is 13 mg/m(2) once every 21 days.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:57:06 GMT 2025
by
admin
on
Wed Apr 02 06:57:06 GMT 2025
|
| Record UNII |
1V8X590XDP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1904
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1V8X590XDP
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
CHEMBL435191
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
C2665
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
8246
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
100000089430
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
m4830
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB04882
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
DTXSID40870123
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
C121395
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
174402-32-5
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
9808998
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
RR-32
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY | |||
|
SUB25404
Created by
admin on Wed Apr 02 06:57:06 GMT 2025 , Edited by admin on Wed Apr 02 06:57:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|